Australian database linkages could be used for postmarketing surveillance of antidiabetic therapy side effects
Several incretin hormone-based therapies for type 2 diabetes are marketed in Australia. These are exenatide (the glucagon-like peptide-1 [GLP-1] analogue) and sitagliptin, vildagliptin and saxagliptin (inhibitors of the enzyme dipeptidyl-peptidase-4 [DPP-4]). These drugs are attractive because they improve blood glucose control without weight gain and with less hypoglycaemia than insulin and its secretagogues. Their distinct mode of action means that they improve glycaemic control when added to more established blood glucose-lowering therapies. This underlies their current Pharmaceutical Benefits Scheme listing as part of dual or, in the case of exenatide, triple therapy with metformin and/or sulfonylurea treatment.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.